Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Stopped Lack of enrollment due to evolution of COVID-19 pandemic with reduction in patients at risk for severe disease and growing number of effective alternative therapies
Conditions
Interventions
- DRUG: Zavegepant (BHV-3500)
- DRUG: Placebo
Sponsor
Pfizer